Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 studyJianming Xu, Weiguo Su, Chunmei Bai et al.|The Lancet Oncology|2020Cited by 193
Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p)Jianming Xu, Weiguo Su, Lin Shen et al.|European Journal of Cancer|2025Cited by 4